Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox®/Asasantin®) in France
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: To assess the cost effectiveness of aspirin 25mg plus dipyridamole 200mg twice daily in the secondary prevention of ischaemic stroke, according to the French social security perspective, using efficacy data from the second European Stroke Prevention Study (ESPS-2). The ESPS-2 was a double-blind, placebo-controlled clinical trial which assessed the efficacy of four secondary prevention strategies: (i) placebo; (ii) aspirin (acetylsalicylic acid) 25mg twice daily; (iii) dipyridamole 200mg twice daily; and (iv) aspirin 25mg plus dipyridamole 200mg twice daily.
Method: We performed a cost-effectiveness analysis with Monte Carlo simulations to compute confidence intervals. We combined data from various sources including the Dijon Stroke Registry, Institut National de la Statistique et des Etudes Economiques, Etude du Coût de l’Infarctus Cérébral (Study of the Cost of Cerebral Infarction [ECIC]) study and the ESPS-2 trial.
Results: According to our findings, a preventive strategy with aspirin 25mg plus dipyridamole 200mg twice daily is associated with net benefits per avoided stroke recurrence amounting to $US23 932 (95% CI -$US32 609, $US35 772) compared with aspirin 25mg twice daily alone, and $US31 555 (95% CI $US4921, $US74 515) compared with dipyridamole alone (1997 values). Sensitivity analysis demonstrated that dipyridamole plus aspirin was still cost effective when the average cost of adverse effects per episode (ignored in the original estimation of the cost-effectiveness ratios due to a lack of data) was assumed to be $US8600 (50 000 French francs); this cost is unlikely as most of the adverse effects associated with aspirin plus dipyridamole are only slight to moderate in severity.
Conclusions: In the secondary prevention of stroke in France, this study suggests, given its underlying assumptions and data, that aspirin 25mg plus dipyridamole 200mg twice daily is likely to be a cost-effective strategy from the social security perspective, when compared with other relevant strategies that were evaluated in the ESPS-2 trial.
- Van Bergen PFMM, Jonker JJC, van Hout BA, et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995; 273 (12): 925–8
- Scott, G, Scott, HM (1997) Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis. Pharmacoeconomics 12: pp. 667-74 CrossRef
- Chambers, M, Hutton, J, Gladman, J (1999) Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics 16: pp. 577-93 CrossRef
- Sarasin, FP, Gaspoz, JM, Bounameaux, H (2000) Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med 160: pp. 2773-8 CrossRef
- Marissal, JP, Selke, B, Lebrun, T (2000) Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics 18: pp. 185-200 CrossRef
- Giroud, M, Milan, C, Beuriat, P (1991) Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks. The Stroke Registry of Dijon: 1985-1989. Int J Epidemiol 20: pp. 892-9 CrossRef
- Lemesle, M, Milan, C, Faivre, J (1999) Incidence trends of ischemic stroke and transient ischemic attacks in a well-defined French population from 1985 through 1994. Stroke 30: pp. 371-7 CrossRef
- Emploi. Tableaux de l’éeconomie fran¸caise. INSEE, Paris, pp. 72-3
- Mercier MA, Lee P. Le marcheé du travail en France et au Royaume-Uni. Paris: INSEE Première n°670, 1999: 4
- Spieler JF, Lanoe¨ JL, Amarenco P. La prise en charge des patients atteints d’infarctus céeréebral en France: analyse des fili`eres de soins et éevaluation de leur coˆut. L’éetude ECIC: 88 pages, Paris [unpublished paper]
- Spieler, JF (2002) Lano¨e JL, Amarenco P. Socioeconomic aspects of postacute care for patients with brain infarction in France. Cerebrovasc Dis 13: pp. 132-41 CrossRef
- Diener, HC, Cunha, L, Forbes, C (1996) European Stroke Prevention Study: II. Dipyridamole and aspirin in the secondary prevention of stroke. J Neurol Sci 143: pp. 1-13 CrossRef
- Garber, AM, Phelps, CE (1997) Economic foundations of cost-effectiveness analysis. J Health Econ 16: pp. 1-31 CrossRef
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: pp. 1329-39 CrossRef
- Collaborative overview of randomised trials of antiplatelet therapy: I. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: pp. 81-106 CrossRef
- Patrono, C, Coller, B, Dalen, JE (2001) Platelet-active drugs: the relationships among dose, effectiveness and side effects. Chest 119: pp. 39-63 CrossRef
- Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox®/Asasantin®) in France
Volume 22, Issue 10 , pp 661-670
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors